US equities
|
INTC
$66.17
▼-28.13%
AMZN
$241.25
▼-1.04%
MU
$891.78
▼-4.55%
NVDA
$206.53
▼-3.33%
GOOGL
$282.40
▼-0.50%
SNDK
$1,192.44
▼-10.35%
SPCX
$138.28
▼-3.90%
AMD
$514.67
▼-9.14%
INTC
$66.17
▼-28.13%
AMZN
$241.25
▼-1.04%
MU
$891.78
▼-4.55%
NVDA
$206.53
▼-3.33%
GOOGL
$282.40
▼-0.50%
SNDK
$1,192.44
▼-10.35%
SPCX
$138.28
▼-3.90%
AMD
$514.67
▼-9.14%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
ZyVersa Therapeutics, Inc. - Common Stock
(NQ:
ZVSA
)
0.3113
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Jul 16, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about ZyVersa Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
ZyVersa Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
May 13, 2026
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update
March 31, 2026
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Reports Third Quarter 2025 Financial Results
November 19, 2025
From
ZyVersa Therapeutics
Via
GlobeNewswire
Nasdaq's Delisting Wave: Navigating the Shifting Tides of Public Markets
September 24, 2025
The Nasdaq Stock Market has seen a notable increase in delistings over recent periods, signaling a recalibration of public market standards and a challenging environment for certain companies. This...
Via
MarketMinute
Topics
Bankruptcy
Fraud
Regulatory Compliance
ZyVersa Therapeutics Highlights Data Reinforcing the Potential of Inflammasome Inhibitors to Attenuate Progression of Type 2 Diabetes and Improve Associated Long-term Cardiovascular Outcomes
September 10, 2025
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Highlights Lipidomic Data in Alport Syndrome and DKD Reinforcing the Need for Drugs to Attenuate Damaging Renal Lipid Accumulation to Mitigate Disease Progression
September 03, 2025
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Highlights Data Demonstrating a Critical Need for Therapies to Address Kidney Lipotoxicity to Alleviate Diabetic Kidney Disease (DKD) and Its Progression
August 14, 2025
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Reports Second Quarter 2025 Financial Results and Highlights Key Near-term Value-building Milestones
August 13, 2025
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics CEO Issues Mid-year Shareholder Letter Highlighting Recent Corporate Developments and R&D Progress
July 21, 2025
From
ZyVersa Therapeutics
Via
GlobeNewswire
Curious about the stocks that are showing activity after the closing bell on Friday?
↗
July 18, 2025
The regular session of the US market on Friday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.
Via
Chartmill
Which stocks are moving after the closing bell on Thursday?
↗
July 17, 2025
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
Via
Chartmill
Top movers analysis one hour before the close of the markets on 2025-07-16: top gainers and losers in today's session.
↗
July 16, 2025
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Via
Chartmill
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
July 16, 2025
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
July 09, 2025
Via
Benzinga
These stocks are moving in today's pre-market session
↗
July 09, 2025
As the US market prepares to open on Wednesday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Via
Chartmill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
July 09, 2025
Via
Benzinga
Top movers in Tuesday's session
↗
July 08, 2025
Let's have a look at what is happening on the US markets one hour before the close of the markets on Tuesday. Below you can find the top gainers and losers in today's session.
Via
Chartmill
Most active stocks in Tuesday's session
↗
July 08, 2025
Let's have a look at what is happening on the US markets on Tuesday. Below you can find the most active stocks in today's session.
Via
Chartmill
Why Did ZyVersa Therapeutics Stock Shoot Higher On Tuesday?
↗
July 08, 2025
ZyVersa gains FDA approval for emergency use of VAR 200 in a rare kidney disease case; stock jumps on high trading volume and regulatory momentum.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
July 08, 2025
Via
Benzinga
What's going on in today's session
↗
July 08, 2025
Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.
Via
Chartmill
ZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross Proceeds
July 08, 2025
From
ZyVersa Therapeutics
Via
GlobeNewswire
Tuesday's pre-market session: top gainers and losers
↗
July 08, 2025
Wondering what's happening in Tuesday's pre-market session? Find an overview in this article.
Via
Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
July 08, 2025
Via
Benzinga
ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator™ VAR 200 in a Patient with ApoCII Amyloidosis
July 08, 2025
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Announces First Clinical Site Activation, Initiating Patient Recruitment for Cholesterol Efflux Mediator™ VAR 200’s Phase 2a Clinical Trial in Patients with Diabetic Kidney Disease (DKD)
June 26, 2025
From
ZyVersa Therapeutics
Via
GlobeNewswire
Why Worthington Steel Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket
↗
June 26, 2025
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
June 25, 2025
Via
Benzinga
ZyVersa Therapeutics Announces Share Purchase Agreement for up to $10 Million in Partnership with Williamsburg Venture Holdings to Fund Clinical Development of Cholesterol Efflux Mediator™ VAR 200
June 25, 2025
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Highlights Published Study Reinforcing That Microglia-driven Inflammation Is Pivotal in Development of Parkinson’s and Alzheimer’s Diseases
May 20, 2025
From
ZyVersa Therapeutics
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
